Bo Ran, Yasen Aimaiti, Shao Yingmei, Zhang Wenbao, Lin Renyong, Jiang Tiemin, Wen Hao, Xiao Hui, Aji Tuerganaili
1Department of Liver Hydatid Disease, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011 Xinjiang Uyghur Autonomous Region People's Republic of China.
2School of Public Health, Xinjiang Medical University, Urumqi, 830011 Xinjiang Uyghur Autonomous Region People's Republic of China.
Infect Agent Cancer. 2020 Jan 29;15:5. doi: 10.1186/s13027-020-0275-0. eCollection 2020.
Co-existence of hepatocellular carcinoma (HCC) and cystic echinococcus (CE) is extremely rare. may exhibit a protective effect against cancer. Herein, this study aimed to evaluate the possible effects of echinococcal infection on HCC patients.
Three thousand three hundred hepatic CE patients and 815 HCC patients were retrospectively reviewed between January 2010 and December 2018 in Xinjiang, China, and these patients were 1:5 matched according to their sex, age and tumor TMN stage, and only 13 patients coexisted both CE and HCC. Preoperative ultrasonography (US), computed tomography (CT), liver magnetic resonance imaging (MRI) and dot immune-gold filtration assay (DIGFA) were used for preoperative identification and intraoperative specimens from liver resections were pathologically examined for further confirmation. Survival time was analyzed through Cox proportional hazard model analysis.
The co-existing incidence rate of two diseases was 0.39%. For these concurrent cases, HCC was all at the advanced stage and CE lesions were inactive. Median survival time for HCC patients was 6 month (1-17). However, it was 8 month (3-90) for the co-existing cases and was much longer than the median survival time of HCC patients (<0.05), which was closely associated with tumor size, location, TMN stage and hydatid size, location, classification. Four of the patients underwent surgical intervention and their median survival time was 17 month (3-68).
may elicit a protective effect against the development and progression of HCC, while more basic and clinical researches are needed.
肝细胞癌（HCC）与囊性棘球蚴病（CE）并存极为罕见。CE可能对癌症具有保护作用。在此，本研究旨在评估棘球蚴感染对HCC患者的可能影响。
回顾性分析2010年1月至2018年12月在中国新疆的3300例肝CE患者和815例HCC患者，这些患者根据性别、年龄和肿瘤TMN分期进行1:5匹配，仅有13例患者同时存在CE和HCC。术前采用超声（US）、计算机断层扫描（CT）、肝脏磁共振成像（MRI）和斑点免疫金过滤试验（DIGFA）进行术前鉴别，并对肝切除术中的标本进行病理检查以进一步确诊。通过Cox比例风险模型分析生存时间。
两种疾病的并存发生率为0.39%。对于这些并发病例，HCC均处于晚期且CE病灶不活跃。HCC患者的中位生存时间为6个月（1 - 17个月）。然而，并存病例的中位生存时间为8个月（3 - 90个月），远长于HCC患者的中位生存时间（<0.05），这与肿瘤大小、位置、TMN分期以及包虫大小、位置、分类密切相关。4例患者接受了手术干预，他们的中位生存时间为17个月（3 - 68个月）。
CE可能对HCC的发生和发展产生保护作用，同时还需要更多的基础和临床研究。
